ClinicalTrials.gg
CompletedNCT04309643Updated Jul 16, 2020

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

A Phase 1 interventional study of CTP-543 and Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG) in Healthy Volunteers, sponsored by Concert Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-16.

Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2020, 6 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

This is a Phase 1, fixed sequence, multiple dose, open-label study of the effect of CTP-543 on oral contraceptive pharmacokinetics in healthy female subjects.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Oral contraceptive
  • Drug-drug Interaction
  • CTP-543
03

In context

Lead sponsor

Concert Pharmaceuticals is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.

First submitted before Concert Pharmaceuticals became part of Sun Pharmaceutical Industries Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female participants of non-, or adult females of childbearing potential who agree to use methods described in the protocol
  • If of reproductive age, willing and able to use a medically highly effective form of birth control 28 days prior to first dose, during the study and for 28 days following last dose of study medication. Examples of medically highly effective forms of birth control are:

    1. Surgical sterilization of the partner (via vasectomy, hysterectomy, bilateral tubal ligation or bilateral salpingectomy) at least 4 months prior to first dose or with amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels (> 40 IU/L) consistent with postmenopausal status
    2. Sexual partner is sterile, or of the same sex
    3. Double-barrier method (any combination of physical and chemical methods)
    4. Non-hormone releasing intrauterine device in females
  • Continuous non smoker who has not used nicotine containing products for at least 3 months prior to the first dosing and throughout the study
  • (BMI) ≥ 18.0 and ≤ 32.0 kg/m2
  • Medically healthy with no medical history, physical examination, laboratory tests, vital signs, or ECGs
  • Understands the study procedures in the form, and be willing and able to comply with the protocol

Exclusion criteria

Exclusion Criteria:

  • Positive pregnancy test
  • History or presence of medical or psychiatric condition or disease
  • History of any illness that might confound the results of the study or pose an additional risk to the subject by their participation in the study
  • History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing
  • A positive tuberculosis test at screening or history of incompletely treated or untreated tuberculosis
  • Positive results at screening for (HIV), surface antigen (HBsAg) or virus (HCV)
  • Donation of blood or significant blood loss within 56 days prior to dosing
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    CTP-543

    In Period 1, participants will receive a single oral dose of the combination oral contraceptive (OC) on Day 1. There will be a washout period of 7 days between dosing in Period 1 and the first dose in Period 2. In Period 2, participants will receive twice daily oral doses of CTP-543 for 8 consecutive days with a single dose of the combination OC co-administered on Day 4.

    Drug: CTP-543 · Drug: Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)

Interventions

  • Investigational Drug

  • DrugCombined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)

    Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Area Under the Plasma Concentration-Time Profile

    Time frame: From the start of Period 1 to completion of Period 2 (16 days)

  2. AUC0-inf

    Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time

    Time frame: From the start of Period 1 to completion of Period 2 (16 days)

  3. Cmax

    Maximum observed concentration of drug in plasma

    Time frame: From the start of Period 1 to completion of Period 2 (16 days)

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An adverse event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

    Time frame: Up to 58 days

  2. Number of Participants With Clinically Significant Change in Vital Signs

    Blood pressure, heart rate, respiratory rate, and temperature

    Time frame: Up to 44 days

  3. Number of Participants With Clinically Significant Change in Clinical Laboratory Evaluations

    Hematology, serum chemistry, coagulation, and urinalysis

    Time frame: Up to 44 days

  4. Number of Participants With Clinically Significant Change to the Physical Examination

    Symptom-driven physical examinations may be performed at other times, if deemed necessary

    Time frame: Screening (Day -28)

  5. Number of Participants With Clinically Significant Change in Electrocardiogram

    12-Lead ECG

    Time frame: Up to 40 days

07

Study locations

1 site
  • Celerion, Inc.
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Jun 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2020
First posted
Mar 16, 2020
StartActual
Jun 9, 2020
Primary completionActual
Jun 25, 2020
CompletionActual
Jul 8, 2020
Last update
Jul 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04309643
Collaborators
Celerion
Responsible party
Sponsor
First posted
Mar 16, 2020
Start date
Jun 9, 2020
Primary completion
Jun 25, 2020
Completion
Jul 8, 2020
Last update
Jul 16, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion